Company intelligence / Profile preview

Raphas

Ownership: Private
Development stage: Commercial

Overview

Raphas has demonstrated preclinical proof-of-concept for its microneedle platform delivering peptides, allergens, and nucleic acids with preserved efficacy and stability. The company is actively seeking partners to advance programs into later-stage clinical trials and commercialization.

Therapeutic areas: ImmunologyMetabolic Disorders
Modalities: Microneedle-based drug delivery systemPeptides (e.g., GLP-1)Nucleic acids (DNA, mRNA)BiologicVaccine patchAllergen immunotherapy patch
Industry: Biotech

Drug pipeline

9 assets

DF19001

8 more assets in the full pipeline.

Request access →

Partnerships

Actively seeking co-development/product commercialization/licensing partners globallyhistory of collaboration with raw material medicine corporations

Beyond the preview

Go deeper on Raphas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Raphas.

Explore the full profile